Status:
AVAILABLE
Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection
Lead Sponsor:
Avobis Bio, LLC
Collaborating Sponsors:
Alimentiv Inc.
Conditions:
Perianal Fistula Due to Crohn's Disease
Eligibility:
All Genders
Brief Summary
The goal of this Expanded Access Protocol is to provide expanded access of AVB-114 to patients who had their fat tissue collected as part of a clinical trial (STOMP-II), but who were subsequently not ...
Detailed Description
AVB-114 is an autologous investigational product under evaluation in Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II; a prospective, multicenter, randomized, blinded outcome a...
Eligibility Criteria
Inclusion
- Provision of signed and dated ICF.
- Adipose tissue previously collected per the STOMP-II protocol, but were subsequently unable to receive AVB-114 treatment due to screen failure or product manufacturing issues and thus withdrew.
- Diagnosed with Crohn's disease and a target perianal fistula with one internal opening and at least one external opening.
Exclusion
- Suffer from any condition or illness that, in the opinion of the Investigator, would compromise patient safety.
- Pregnant, trying to become pregnant, or are breast feeding. Women of childbearing potential (WCBP) and males who have sexual partners that are WCBP must agree to use an adequate method of contraception while participating in this EAP.
- Known allergies or hypersensitivity to aminoglycosides.
- History of clinically significant fat-directed autoimmunity.
- Active, unresolved infection requiring parenteral antibiotics.
- Unresolved abscess at time of treatment (if screening Pelvic MRI identifies an abscess, it must be resolved before treatment).
- Target fistula with any of the following characteristics (note that presence of a second fistula tract that is distinctly separate from the target fistula, or a target fistula with a single internal opening and multiple external openings is not exclusionary):
- Target fistula has a branching blind ending sinus tract (no external opening) that investigator assesses to be at elevated risk of abscess formation if treated with AVB-114.
- Target fistula is a genito-urinary fistula, including rectovaginal (i.e., fistulae that transverse the vaginal canal).
- Any anatomical limitation to successfully securing the fistula plug disk.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06509828
Last Update
July 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.